In order to evaluate further the potential benefit of prophylactic intramuscular lidocaine administration in coronary artery disease, 24 patients with suspected acute myocardial infarction were given an intramuscular injection of lidocaine (10% solution) in the deltoid and gluteal muscles on consecutive days. Twelve patients received an intermediate dose (4 mg/kg), and 12 received a high dose (6 mg/kg) of lidocaine, and blood lidocaine levels were measured over a 4-hour study period.
SUMMARY
In order to evaluate further the potential benefit of prophylactic intramuscular lidocaine administration in coronary artery disease, 24 patients with suspected acute myocardial infarction were given an intramuscular injection of lidocaine (10% solution) in the deltoid and gluteal muscles on consecutive days. Twelve patients received an intermediate dose (4 mg/kg), and 12 received a high dose (6 mg/kg) of lidocaine, and blood lidocaine levels were measured over a 4-hour study period.
Intradeltoid injection produced higher blood lidocaine levels and more rapid development of peak blood levels than did intragluteal injection. Administration of high-dose lidocaine (average dose 450 mg) into the deltoid muscle produced the ideal combination of rapid peak blood levels (6.5 gg/ml 2.1 SEM at 5 min) and persistence of therapeutic levels (>1.5 ,ug/ml) for over 2 hours. Although drowsiness, paresthesias, slurred speech, and tinnitus occurred in seven of the 12 patients in the high-dose group, no major neurotoxicity, such as grand mal seizures, were observed, nor was there evidence of hypotension or increase in atrioventricular block. Prophylactic administration of high-dose 10% lidocaine into the deltoid muscle appears to have potential for reducing the early mortality following acute myocardial infarction.
Additional Indexing Words:
Prophylactic administration Pharmacokinetics PREVIOUS STUDIES have demonstrated that the major mortality following myocardial infarction occurs prior to hospitalization.' In one study, 25% of coronary deaths occurred within 5 min, and 38% occurred within 1 hour of the onset of symptoms.2 Ventricular arrhythmias leading to ventricular fibrillation are considered the most common mechanism of this early mortality.3 Since prophylactic administration of intravenous lidocaine has been shown to reduce the in-hospital incidence of ventricular tachycardia and fibrillation in acute myocardial infarction,4 6 it has been suggested that early prophylactic administration of intramuscular lidocaine prior to hospitalization in patients developing symptoms might reduce this early arrhythmic mortality. 7, 8 From the Cardiology Division, Stanford University School of Medicine, Stanford, California.
Supported in part by National Institutes of Health Grants HL-5709 and HL-5866.
Several reports have shown that the intramuscular administration of 200-300 mg of lidocaine results in plasma lidocaine levels in the lower therapeutic range within 10-30 min, which persist for over 1 hour.9-11 The present study was designed to evaluate: (1) the effects of higher doses of intramuscular lidocaine, injected in two different sites, on both the rate of drug absorption and on the magnitude of lidocaine blood levels; and (2) the safety of administering large doses of lidocaine intramuscularly to patients with acute myocardial infarction. Of the 24 patients studied, 14 were subsequently classified as definitely, and five probably, sustaining an acute myocardial infarction. In the remaining five there was no evidence of acute myocardial damage. Excluded from the study group were all patients with atrioventricular block greater than first degree, with preceding cardiac arrest or cardiogenic shock. Patients with a moderate degree of congestive heart failure were not excluded.
All study patients were under continuous electrocardiographic monitoring; vital signs were obtained prior to the injection and at 2-hour intervals thereafter. The patients were closely observed and questioned regarding signs and symptoms of lidocaine neurotoxicity throughout each 4-hour study period.
Results
Blood lidocaine levels were related to both the dose and the location of injection. Following administration of the intermediate dose (4 mg/kg), mean blood levels peaked at 15 min reaching low (1.5 gug/ml) and moderate (2.5 gg/ml) therapeutic levels after intragluteal and intradeltoid injection, respectively ( fig. 1) High-dose (6 mg/kg) im lidocaine resulted in significantly higher blood levels (P<0.05) compared to the intermediate dose from 10 through 180 min following both intradeltoid and intragluteal injections ( fig. 2 ). In addition, at the higher dose the rate of drug absorption from the two injection sites differed markedly. Intradeltoid administration resulted in the much more rapid development of peak blood levels than did the intragluteal injection (5 vs 30 min). Mean blood lidocaine levels from 5 through 120 min were also significantly higher following intradeltoid than following intragluteal injection. Blood lidocaine levels after high-dose intradeltoid injection persisted in the high therapeutic range for at least 30 min and remained over 1.5 ,ug/ml for more than 2 hours. Only one of the 12 patients failed to develop a blood level over 2.0 ,ug/ml within 10 min of the high-dose intradeltoid injection.
Patient acceptance of the intramuscular lidocaine injection was excellent. The injection resulted in minimal immediate discomfort, although mild tenderness at the injection site developed in some The ideal antiarrhythmic drug to reduce the early mortality of coronary artery disease would be an effective, long-acting oral agent without significant side effects or cardiodepressive activity. In the absence of such an agent, new routes of administration have been explored for the in-hospital drug of choice, lidocaine. The oral route for lidocaine has not proved satisfactory, due to subtherapeutic plasma lidocaine levels attained despite large doses, the delay in peak blood levels (30-60 min after ingestion), variable gastrointestinal symptoms, and the prominence of neurotoxic symptoms. 10' 14 Several reports indicate that the im administration of 200-300 mg of lidocaine results in low-tomodest therapeutic blood levels within 10-30 min, which persist for over 1 hour.9-1" Since ventricular arrhythmias occur most frequently at the onset of myocardial infarction and may be relatively lidocaine-resistant,15 the rapid development of high therapeutic lidocaine blood levels is desirable. The use of combined i.v. and im lidocaine administration has been suggested for this goal,'6 but is not practical for prophylactic self-administration at the onset of severe chest pain. Our data indicate that intramuscular administration of high-dose (450 mg) 10% lidocaine into the deltoid muscle combines the virtues of both the i.v. and im routes, i.e., the rapid development of high therapeutic blood levels and the persistence of therapeutic levels for over 2 hours.
Pharmacokinetic analysis ( fig. 3) 20 Cohen and associates, however, recently reported that lidocaine plasma levels attained in man were inversely related to the concentration of the drug in the range of 6-10%.11 These findings should be confirmed by other investigators, since the administration of larger volumes will be required with lower concentrations. Even with the use of 10% solutions and reasonable volumes, we were able to achieve adequate blood levels in all patients studied.
The ability of im lidocaine to suppress ventricular irritability resulting from acute myocardial infarction has been documented and appears to correlate with blood lidocaine concentration as previously described following i.v. administration. 10' 21 The present study indicates that the im administration of high-dose (6 mg/kg) lidocaine is safe in patients with acute myocardial infarction, in the absence of marked bradycardia or cardiogenic shock. No hypotension nor increase in atrioventricular block was noted. The one episode of significant arrhythmia, ventricular tachycardia, developed 2 hours after the injection, when the plasma lidocaine level had already fallen to a subtherapeutic level.
A controlled study of prophylactic self-administration of high-dose im lidocaine at the onset of severe chest pain should now be undertaken in a group of patients at high risk of sustaining an acute myocardial infarction. Since other studies have demonstrated different patterns of absorption with concentrations of lidocaine from 6 to 10%, controlled prophylactic studies should utilize more than one concentration of the drug.
